A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M.
Greenfield WW, et al.
Oncoimmunology. 2015 May 27;4(10):e1031439. doi: 10.1080/2162402X.2015.1031439. eCollection 2015 Oct.
Oncoimmunology. 2015.
PMID: 26451301
Free PMC article.